P&G in China
This article was originally published in The Tan Sheet
Firm announces $1.8 bil. purchase of remaining 20% stake in China joint venture from partner Hutchison Whampoa China. The deal was announced May 11 and is expected to close June 18. CEO A.G. Lafley said "it is the right time for us to assume full ownership" of the China venture, and that recent positive results demonstrate P&G has the "in-depth understanding of local consumers and retailers in China to continue to build this fast-growing business." China is one area where P&G has sought to localize its supply chain, marketing and management (1"The Tan Sheet" May 3, 2004, p. 6)...
You may also be interested in...
Procter & Gamble's Prilosec OTC has garnered nearly a quarter share of the over-the-counter stomach remedy category
Device Week, 05 March - Remote Monitoring Reimbursement, T-cell Diagnostics And A Digital Health Feature
In this week's podcast, managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform.
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.